- Home
- ZENV vs IOBT Comparison
ZENV vs IOBT Comparison
Compare ZENV & IOBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZENV | IOBT |
|---|---|---|
| Founded | 2005 | 2014 |
| Country | Brazil | Denmark |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.9M | 57.2M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ZENV | IOBT |
|---|---|---|
| Price | $0.84 | $0.37 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $2.25 |
| AVG Volume (30 Days) | 28.5K | ★ 28.1M |
| Earning Date | 03-16-2026 | 03-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $201,426,369.00 | N/A |
| Revenue This Year | $12.75 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 24.80 | N/A |
| 52 Week Low | $0.75 | $0.21 |
| 52 Week High | $2.45 | $2.79 |
Technical Indicators
Market Signals| Indicator | ZENV | IOBT |
|---|---|---|
| Relative Strength Index (RSI) | 46.53 | 45.08 |
| Support Level | $0.75 | $0.32 |
| Resistance Level | $0.89 | $0.40 |
| Average True Range (ATR) | 0.07 | 0.04 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 56.83 | 76.55 |
Price Performance
Historical ComparisonAbout ZENV Zenvia Inc.
Zenvia Inc provides a platform that enables companies to create journeys for their end customers across a variety of channels. The company operates in two reportable segments namely CPaaS and SaaS. It has a geographic presence in Brazil, the USA, Argentina, Mexico, and Others. The company generates the majority of its revenue from Brazil.
About IOBT IO Biotech Inc.
IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.